Theoretical considerations for a left atrial pump in heart failure with preserved ejection fraction

被引:0
作者
Hannah Rosenblum
Michael Brener
Daniel Burkhoff
机构
[1] Division of Cardiology,
[2] Department of Medicine Columbia University Irving Medical Center-NYP Hospital,undefined
[3] Cardiovascular Research Foundation,undefined
来源
Heart Failure Reviews | 2023年 / 28卷
关键词
Heart failure with preserved ejection fraction; Advanced heart failure; Mechanical circulatory support; Devices;
D O I
暂无
中图分类号
学科分类号
摘要
Heart failure with preserved ejection fraction (HFpEF) is a heterogenous group of disorders, unified by findings of elevated left atrial and left ventricular filling pressures in the setting of normal systolic function. Medical therapies for HFpEF patients are markedly limited, and these patients are often unable to tolerate conventional left ventricular assist device therapies because of small chamber size. The Synergy System (CircuLite, Inc., Saddle Brook, NJ) was a micropump-based form of mechanical circulatory support in which flow derived from the left atrium was delivered to the subclavian artery. In this review, we discuss the potential role of the Synergy left atrial pump to address the hemodynamic derangements of HFpEF.
引用
收藏
页码:273 / 280
页数:7
相关论文
共 133 条
[1]  
Benjamin EJ(2019)Heart Disease and Stroke Statistics-2019 Update: a report from the American Heart Association Circulation 139 e56-e528
[2]  
Muntner P(2008)Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study) Am J Cardiol 101 1016-1022
[3]  
Alonso A(2006)Trends in prevalence and outcome of heart failure with preserved ejection fraction N Engl J Med 355 251-259
[4]  
Loehr LR(2013)The emerging epidemic of heart failure with preserved ejection fraction Curr Heart Fail Rep 10 401-410
[5]  
Rosamond WD(2018)Trends in hospitalizations and survival of acute decompensated heart failure in four us communities (2005–2014): ARIC Study Community Surveillance Circulation 138 12-24
[6]  
Chang PP(2005)Left heart failure with a normal ejection fraction: identification of different pathophysiologic mechanisms J Card Fail 11 177-187
[7]  
Folsom AR(2016)Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap Circulation 134 73-90
[8]  
Chambless LE(2011)Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial Circ Heart Fail 4 324-331
[9]  
Owan TE(2020)Obese-inflammatory phenotypes in heart failure with preserved ejection fraction Circ Heart Fail 13 e006414-555
[10]  
Hodge DO(2020)Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning Heart 106 342-1103